USD 0.11
(0.0%)
Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - |
Cost of Revenue | 54.56 Thousand | 7307.00 | 8642.00 | 9199.00 | 6339.00 | 4369.00 |
Gross Profit | -54.56 Thousand | -7307.00 | -8642.00 | -9199.00 | -6339.00 | -4369.00 |
Operating Expenses | 3.89 Million | 593.73 Thousand | 746.96 Thousand | 2.73 Million | 1.06 Million | 1.94 Million |
Selling, General and Administrative Expenses | 1.44 Million | 165.5 Thousand | 258.14 Thousand | 728.18 Thousand | 475.03 Thousand | 756.09 Thousand |
Research and Development Expenses | - | 124.47 Thousand | 65.55 Thousand | - | - | - |
Other Expenses | - | - | 28.98 Thousand | - | - | - |
Cost and Expenses | 3.95 Million | 601.03 Thousand | 755.6 Thousand | 2.74 Million | 1.06 Million | 1.95 Million |
Operating Income | -3.24 Million | -207.11 Thousand | -747.16 Thousand | -1.87 Million | -892.49 Thousand | -1.45 Million |
Interest Expense | - | - | - | - | - | - |
Income Tax Expense | - | 387.49 Thousand | 8066.00 | 863.69 Thousand | 174.63 Thousand | 487.66 Thousand |
Earnings before Tax | -3.94 Million | -988.52 Thousand | -734.68 Thousand | -3.6 Million | -1.24 Million | -2.44 Million |
Net Income | -3.94 Million | -988.52 Thousand | -734.68 Thousand | -3.6 Million | -1.24 Million | -2.44 Million |
Earnings Per Share Basic | -0.13 | -0.04 | -0.05 | -0.36 | -0.22 | -0.52 |
Earnings Per Share Diluted | -0.13 | -0.04 | -0.05 | -0.36 | -0.22 | -0.52 |
Weighted Average Shares Outstanding | 30.95 Million | 22.03 Million | 13.94 Million | 9.89 Million | 5.74 Million | 4.65 Million |
Weighted Average Shares Outstanding (Diluted) | 30.95 Million | 22.03 Million | 13.94 Million | 9.89 Million | 5.74 Million | 4.65 Million |
Gross Margin | - | - | - | - | - | - |
EBIT Margin | - | - | - | - | - | - |
Profit Margin | - | - | - | - | - | - |
EBITDA | -1.5 Million | -199.8 Thousand | -738.52 Thousand | -1.86 Million | -886.15 Thousand | -1.45 Million |
Earnings Before Tax Margin | - | - | - | - | - | - |
Breakdown | 2024 FY | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY |
---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - |
Cost of Revenue | 4546.00 | 123.00 | 965.00 | 1766.00 | 1692.00 | 7307.00 |
Gross Profit | -4546.00 | -123.00 | -965.00 | -1766.00 | -1692.00 | -7307.00 |
Operating Expenses | 1.54 Million | 330.74 Thousand | 563.31 Thousand | 438.08 Thousand | 212.31 Thousand | 593.73 Thousand |
Selling, General and Administrative Expenses | - | 312.15 Thousand | 106.23 Thousand | 144.65 Thousand | 211.35 Thousand | - |
Research and Development Expenses | - | 8424.00 | 1170.00 | 4188.00 | 40.78 Thousand | - |
Other Expenses | -3370.00 | -18.59 Thousand | 16.18 Thousand | - | -960.00 | - |
Cost and Expenses | 1.54 Million | 330.86 Thousand | 564.28 Thousand | 439.85 Thousand | 214 Thousand | 601.03 Thousand |
Operating Income | -1.54 Million | -330.86 Thousand | -611.97 Thousand | 414.85 Thousand | -214.01 Thousand | -207.11 Thousand |
Interest Expense | - | - | - | - | - | - |
Income Tax Expense | 4.00 | -3.00 | -50.52 Thousand | 852.05 Thousand | -2.00 | 387.49 Thousand |
Earnings before Tax | -3.94 Million | -1.89 Million | -513.76 Thousand | -1.29 Million | -237.86 Thousand | -988.52 Thousand |
Net Income | -3.94 Million | -1.89 Million | -513.76 Thousand | -1.29 Million | -237.86 Thousand | -988.52 Thousand |
Earnings Per Share Basic | - | -0.05 | -0.02 | -0.05 | -0.01 | - |
Earnings Per Share Diluted | - | -0.05 | -0.02 | -0.05 | -0.01 | - |
Weighted Average Shares Outstanding | 30.95 Million | 37.92 Million | 34.19 Million | 25.86 Million | 25.86 Million | 22.03 Million |
Weighted Average Shares Outstanding (Diluted) | 30.95 Million | 37.92 Million | 34.19 Million | 25.86 Million | 25.86 Million | 22.03 Million |
Gross Margin | - | - | - | - | - | - |
EBIT Margin | - | - | - | - | - | - |
Profit Margin | - | - | - | - | - | - |
EBITDA | - | -330.74 Thousand | -611.01 Thousand | 414.85 Thousand | -212.32 Thousand | - |
Earnings Before Tax Margin | - | - | - | - | - | - |
GOGL
OILRF
CORA
JLL
CORALFINAC
603955